Proteomics International Laboratories (ASX:PIQ) - Managing Director, Dr Richard Lipscombe
Managing Director, Dr Richard Lipscombe
Source: Proteomics International
The Market Online - At The Bell

Join our daily newsletter At The Bell to receive exclusive market insights

  • Proteomics International (PIQ) has received firm commitments to undertake a $6 million share placement
  • 12.5 million shares will be issued to sophisticated and professional investors at 48 cents each
  • Additionally, the company will issue 2.2 million options to Euroz Hartleys Securities and Candour Advisory
  • These options will have an exercise price of 75 cents with expiry two years after issue
  • Proteomics will use the funds to manufacture, market, and speed-up regulatory approvals for its PromarkerD test and strengthen its balance sheet
  • PromarkerD is a simple blood test the uses a unique protein ‘fingerprint’ to detect diabetic kidney disease up to four years before the symptoms appear
  • Proteomics is up 9 per cent on the market with shares trading for 60 cents each

Proteomics International (PIQ) has received firm commitments to undertake a $6 million share placement.

The medical technology company entered a trading halt on Wednesday but did not disclose how much it will be raising.

All up, 12.5 million shares will be issued to sophisticated and professional investors at 48 cents each, representing a 14.9 per cent discount to the 20-day volume weighted average price.

Shares are expected to be issued on or around November 2.

Euroz Hartleys Securities acted as Sole Lead Manager and Bookrunner while Candour Advisory acted as Corporate Advisor.

Additionally, Proteomics will issue 1.1 million options to both Euroz Hartleys and Candour Advisory.

These options will have an exercise price of 75 cents with expiry two years after issue.

Proteomics will use the funds to manufacture, market, and speed-up regulatory approvals for its PromarkerD test and strengthen its balance sheet.

PromarkerD is a simple, low-cost blood test which uses a unique protein ‘fingerprint’ to detect the onset of diabetic kidney disease up to four years before the symptoms appear.

“We are delighted with the enormous level of support received both from new and existing investors, including U.K. and Australian institutions,” Managing Director Dr Richard Lipscombe said.

“Following the recent achievement for PromarkerD, these funds will drive the delivery of the test into major global markets,” he added.

Proteomics is up 9 per cent on the market with shares trading for 60 cents each at 12:41 pm AEDT.

piq by the numbers
More From The Market Online

Emvision Medical Devices unlocks traumatic brain injury First Responder with $3m grant

EMVision Medical Devices has been awarded a $3 million grant the Australian government’s national CRC-P program.

Immutep obtains encouraging disease-free survival in phase II sarcoma trial

Immutep has unveiled new data from the investigator-initiated EFTISARC-NEO Phase II study evaluating radiotherapy before surgery.

Xenitra signs JD Health strategic Chinese agreement targeting $100m in sales

Xenitra subsidiary Shengdi Pharmaceutical has entered into a three-year strategic agreement with China’s largest online healthcare…

Racura Oncology receives positive results in study of RC110 and RC220

Racura Oncology has obtained positive results from a study into RC220, the company’s proprietary formulation of…